KR102636166B1 - GPR120 조절제로서의 테트라하이드로-벤조[d]아제핀 유도체 - Google Patents
GPR120 조절제로서의 테트라하이드로-벤조[d]아제핀 유도체 Download PDFInfo
- Publication number
- KR102636166B1 KR102636166B1 KR1020197031368A KR20197031368A KR102636166B1 KR 102636166 B1 KR102636166 B1 KR 102636166B1 KR 1020197031368 A KR1020197031368 A KR 1020197031368A KR 20197031368 A KR20197031368 A KR 20197031368A KR 102636166 B1 KR102636166 B1 KR 102636166B1
- Authority
- KR
- South Korea
- Prior art keywords
- optionally substituted
- delete delete
- alkyl
- halo
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1704714.3A GB201704714D0 (en) | 2017-03-24 | 2017-03-24 | Pharmaceutical compounds |
| GB1704714.3 | 2017-03-24 | ||
| PCT/GB2018/000047 WO2018172727A1 (en) | 2017-03-24 | 2018-03-26 | Tetrahydro-benzo[d]azepine derivatives as gpr120 modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190140936A KR20190140936A (ko) | 2019-12-20 |
| KR102636166B1 true KR102636166B1 (ko) | 2024-02-13 |
Family
ID=58687800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197031368A Active KR102636166B1 (ko) | 2017-03-24 | 2018-03-26 | GPR120 조절제로서의 테트라하이드로-벤조[d]아제핀 유도체 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11220483B2 (enExample) |
| EP (1) | EP3601229B1 (enExample) |
| JP (1) | JP7099672B2 (enExample) |
| KR (1) | KR102636166B1 (enExample) |
| CN (1) | CN110891938B (enExample) |
| AU (1) | AU2018238102B2 (enExample) |
| BR (1) | BR112019019868A2 (enExample) |
| CA (1) | CA3057415A1 (enExample) |
| GB (1) | GB201704714D0 (enExample) |
| MX (1) | MX394818B (enExample) |
| WO (1) | WO2018172727A1 (enExample) |
| ZA (1) | ZA201906873B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111712494A (zh) | 2018-02-13 | 2020-09-25 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| EP4600247A3 (en) | 2018-04-19 | 2025-11-19 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| WO2021071837A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
| BR112022017039A2 (pt) | 2020-02-28 | 2022-11-16 | Kallyope Inc | Agonistas de gpr40 |
| JP2023526625A (ja) | 2020-05-19 | 2023-06-22 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
| CN114163426B (zh) * | 2020-09-10 | 2024-03-19 | 上海爱博医药科技有限公司 | 苯并含氧杂环类化合物及其医药应用 |
| US12454511B2 (en) * | 2020-10-08 | 2025-10-28 | Eli Lilly And Company | 6-methoxy-3,4-dihydro-1H-isoquinolin compounds |
| CN114671827B (zh) * | 2020-12-24 | 2024-09-20 | 杭州百新生物医药科技有限公司 | 邻苯甲酰磺酰亚胺类衍生物及其应用 |
| KR102605163B1 (ko) * | 2021-06-01 | 2023-11-23 | 연세대학교 산학협력단 | 뇌암의 예방 또는 치료용 조성물 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008053446A2 (en) | 2006-11-02 | 2008-05-08 | Piramal Life Sciences Limited | Benzoxazepine compounds, their preparation and use |
| WO2016105118A2 (ko) | 2014-12-24 | 2016-06-30 | 주식회사 엘지생명과학 | Gpr120 효능제로서의 바이아릴 유도체 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005282721A1 (en) * | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| EP1940819A1 (en) | 2005-08-16 | 2008-07-09 | Memory Pharmaceuticals Corporation | Phosphodiesterase 10 inhibitors |
| RU2008135126A (ru) * | 2006-01-30 | 2010-03-10 | Айрм Ллк (Bm) | Полициклические производные тетрагидроизохинолина и содержащие их композиции в качестве модуляторов ppar |
| BRPI0807637A2 (pt) * | 2007-02-22 | 2014-06-03 | Irm Llc | Derivados de tiazol como moduladores de receptores acoplados à proteína g |
| CA2725316A1 (en) * | 2008-06-02 | 2009-12-10 | Banyu Pharmaceutical Co., Ltd. | Novel isoxazole derivative |
| WO2013019682A1 (en) | 2011-07-29 | 2013-02-07 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| WO2016022448A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2016022446A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
| WO2017201683A1 (en) * | 2016-05-25 | 2017-11-30 | Merck Sharp & Dohme Corp. | Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists |
-
2017
- 2017-03-24 GB GBGB1704714.3A patent/GB201704714D0/en not_active Ceased
-
2018
- 2018-03-26 EP EP18715236.8A patent/EP3601229B1/en active Active
- 2018-03-26 MX MX2019011314A patent/MX394818B/es unknown
- 2018-03-26 KR KR1020197031368A patent/KR102636166B1/ko active Active
- 2018-03-26 JP JP2020501850A patent/JP7099672B2/ja active Active
- 2018-03-26 CN CN201880033700.7A patent/CN110891938B/zh active Active
- 2018-03-26 US US16/496,786 patent/US11220483B2/en active Active
- 2018-03-26 BR BR112019019868A patent/BR112019019868A2/pt not_active Application Discontinuation
- 2018-03-26 CA CA3057415A patent/CA3057415A1/en active Pending
- 2018-03-26 WO PCT/GB2018/000047 patent/WO2018172727A1/en not_active Ceased
- 2018-03-26 AU AU2018238102A patent/AU2018238102B2/en active Active
-
2019
- 2019-10-18 ZA ZA2019/06873A patent/ZA201906873B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008053446A2 (en) | 2006-11-02 | 2008-05-08 | Piramal Life Sciences Limited | Benzoxazepine compounds, their preparation and use |
| WO2016105118A2 (ko) | 2014-12-24 | 2016-06-30 | 주식회사 엘지생명과학 | Gpr120 효능제로서의 바이아릴 유도체 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019011314A (es) | 2020-01-27 |
| US20200317619A1 (en) | 2020-10-08 |
| JP2020515636A (ja) | 2020-05-28 |
| CN110891938B (zh) | 2023-10-31 |
| AU2018238102A2 (en) | 2019-11-07 |
| RU2019133659A (ru) | 2021-04-26 |
| EP3601229A1 (en) | 2020-02-05 |
| CN110891938A (zh) | 2020-03-17 |
| AU2018238102A1 (en) | 2019-10-31 |
| WO2018172727A1 (en) | 2018-09-27 |
| GB201704714D0 (en) | 2017-05-10 |
| BR112019019868A2 (pt) | 2020-04-22 |
| KR20190140936A (ko) | 2019-12-20 |
| RU2019133659A3 (enExample) | 2021-07-16 |
| JP7099672B2 (ja) | 2022-07-12 |
| EP3601229B1 (en) | 2024-11-06 |
| CA3057415A1 (en) | 2018-09-27 |
| US11220483B2 (en) | 2022-01-11 |
| AU2018238102B2 (en) | 2021-11-04 |
| ZA201906873B (en) | 2022-03-30 |
| MX394818B (es) | 2025-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102636166B1 (ko) | GPR120 조절제로서의 테트라하이드로-벤조[d]아제핀 유도체 | |
| CN105636953B (zh) | 1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途 | |
| JP6163695B2 (ja) | 新しいインダニルオキシフェニルシクロプロパンカルボン酸 | |
| EP3154954B1 (en) | Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof | |
| WO2018006795A1 (zh) | 芳香乙炔或芳香乙烯类化合物、其中间体、制备方法、药物组合物及应用 | |
| JP6441928B2 (ja) | 新規インダニルオキシフェニルシクロプロパンカルボン酸 | |
| TW202003466A (zh) | 人類整合素α４β７拮抗劑 | |
| EP3177282A1 (en) | Antidiabetic bicyclic compounds | |
| WO2020020288A1 (zh) | 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途 | |
| KR20190034318A (ko) | Ido1억제제 및 이의 제조방법과 응용 | |
| CA2891535A1 (en) | Dihydropyrazole gpr40 modulators | |
| KR20220141331A (ko) | P2x3 조정제 | |
| CN109071548A (zh) | 可用于治疗尤其是癌症的吡咯并咪唑衍生物或其类似物 | |
| KR19990007203A (ko) | 아포 비-분비/엠티피 억제제 하이드로클로라이드 염 | |
| CN109651208B (zh) | N-芳基磺酰胺类化合物，其药物组合物及其用途 | |
| CN103145663B (zh) | (s)-2-(2,3-二氢苯并呋喃-3-基)乙酸衍生物，其制备方法及其在医药上的应用 | |
| WO2018219204A1 (zh) | 一类新型苯氧乙酸衍生物、其制备方法及其作为药物的用途 | |
| TW201313684A (zh) | 氮雜螺烷烴化合物 | |
| CN102164905B (zh) | 作为体内缺氧模拟剂的化合物，组合物，及其应用 | |
| CN112028815A (zh) | 吲哚类衍生物及其医药用途 | |
| CN109748914B (zh) | 吡啶并嘧啶类化合物及其应用 | |
| JP2025504791A (ja) | ヒドロキシフェニル部分を含む化合物及びその使用 | |
| RU2776801C2 (ru) | Производные тетрагидробензо[d]азапена в качестве модуляторов as gpr120 | |
| EP3129345A1 (en) | Metabotropic glutamate receptor positive allosteric modulators (pams) and uses thereof | |
| HK40085749A (en) | P2x3 modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20191023 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20201224 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230603 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230822 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20231124 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20240207 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20240207 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |